LABOR. FARMAC. ROVI (ROVI.MC)


MCE - MCE Delayed Price. Currency in EUR
13.34-0.30 (-2.20%)
At close: 11:35 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open13.84
Prev Close13.64
Bid13.10 x 8400
Ask13.81 x 15000
Day's Range13.34 - 13.84
52wk Range11.81 - 15.38
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume51,694
Avg Vol (3m)7,982
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Laboratorios Farmaceúticos Rovi SA : Overvalued relative to peers, but may deserve another look
    Capital Cube2 months ago

    Laboratorios Farmaceúticos Rovi SA : Overvalued relative to peers, but may deserve another look

    Laboratorios Farmaceúticos Rovi SA relative valuation is now OVERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 50.Our analysis is based on comparing Laboratorios Farmaceúticos Rovi SA with the following peers – Almirall SA, Lavipharm S.A., Bioorganic Research & Services SA and Recordati S.p.A. (ALM-ES, LAVI-GR, BNT-ES and REC-IT).Relative ValuationLaboratorios Farmaceúticos […] (Read more...) The post Laboratorios Farmaceúticos Rovi SA : Overvalued relative to peers, but may deserve another look appeared first on CapitalCube.

  • Laboratorios Farmaceúticos Rovi SA : Fairly valued, but don’t skip the other factors
    Capital Cubelast year

    Laboratorios Farmaceúticos Rovi SA : Fairly valued, but don’t skip the other factors

    Laboratorios Farmaceúticos Rovi SA relative valuation is now NEUTRAL. It was previously rated OVERVALUED, and has a fundamental analysis score of 53.Our analysis is based on comparing Laboratorios Farmaceúticos Rovi SA with the following peers – Almirall SA, Lavipharm S.A., Bioorganic Research & Services SA and Recordati S.p.A. (ALM-ES, LAVI-GR, BNT-ES and REC-IT).Relative ValuationLaboratorios Farmaceúticos (Read more...) The post Laboratorios Farmaceúticos Rovi SA : Fairly valued, but don’t skip the other factors appeared first on CapitalCube.

  • Grifols SA : Undervalued relative to peers?
    Capital Cubelast year

    Grifols SA : Undervalued relative to peers?

    Grifols SA relative valuation is now UNDERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 50.Our analysis is based on comparing Grifols SA with the following peers – Baxter International Inc., Almirall SA, Laboratorios Farmaceuticos Rovi, S.A. and Bayer AG (BAX-CH, ALM-ES, ROVI-ES and BAY-ES).Relative ValuationGrifols SA’s price of EUR 28.65 (Read more...) The post Grifols SA : Undervalued relative to peers? appeared first on CapitalCube.